New drug accessibility and budgetary impact in South Korea: policy challenges and implications [0.03%]
韩国新药的可及性和预算影响：政策挑战与含义
Se-Eun Hwang,Yoon-A Jang,Kyung-Min Lim et al.
Se-Eun Hwang et al.
Background: To compare the accessibility indicators for new drugs in South Korea with those in the United States, Europe, and Japan, and examine the structure of pharmaceutical expenditures in South Korea. ...
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China [0.03%]
在中国广泛期小细胞肺癌患者中添加替雷利珠单抗作为一线化疗的综合经济价值评估
Shan Zhao,Shuo Kang
Shan Zhao
Background: The cost-effectiveness of tislelizumab plus chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effective of addin...
COVID-19-related hospitalizations in Italy: an application of the synthetic control method to investigate the trajectory of diagnosis related group 79 and its counterfactual during 2010-2021 [0.03%]
意大利与COVID-19相关的住院治疗：应用合成控制法在2010-2021年间探讨诊断相关组79及其反事实的轨迹变化
Carlo Lazzaro,Giovanni Fattore,Angelo Guido Corsico
Carlo Lazzaro
Background: with 10.95 million cases (11 March 2020-9 February 2022), Italy was massively hit by the coronavirus disease 2019 (COVID-19) pandemic. Most of the COVID-19-related inpatient discharges were codified under Diag...
Comparison of long-term overall survival with extrapolated overall survival for pembrolizumab assessed by Australian reimbursement authorities [0.03%]
澳大利亚药品报销评估机构对帕博利珠单抗长期OS与外推OS的对比分析
Francis C Dehle,Kevin Phan,Jerome Higgins et al.
Francis C Dehle et al.
Background: Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data. This study compared the accuracy o...
Matching-Adjusted Indirect Comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-Cell lymphoma in China [0.03%]
注射用紫杉醇聚合物结合型和西达本胺在治疗中国复发或难治性外周T细胞淋巴瘤的匹配调整间接对比及成本效果分析
Ying Liu,Xiaoning He
Ying Liu
Background: Mitoxantrone hydrochloride liposome (PLM60) is a novel liposome formulation, approved in China for the treatment of patients diagnosed with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This st...
Cost-effectiveness of nintedanib versus Pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review [0.03%]
治疗特发性肺纤维化时，尼达尼布相对于吡非尼酮的成本效果对比：系统性回顾
Aziz Rezapour,Mohammad Veysi-Sheykhrobat,Aghdas Souresrafil et al.
Aziz Rezapour et al.
Introduction: Objective: To systematically review studies on the cost-effectiveness of pirfenidone compared to nintedanib in patients with idiopathic pulmonary fibrosis (IPF). ...
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China [0.03%]
公立医院综合改革对慢性阻塞性肺疾病患者经济负担影响研究——西部试点城市数据分析
Yanghaotian Wu,Jingfu Qiu
Yanghaotian Wu
Background: The Chinese government launched a comprehensive reform of public hospitals, including a zero-markup drug policy (ZMDP) and adjustments to the price compensation mechanism for medical services. We aimed to asse...
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update [0.03%]
欧盟罕见疾病患者药物的获取与定价：行业视角。2025年更新版
Giovanni Tafuri,Andrea Bracco,Jens Grueger
Giovanni Tafuri
Introduction: In a previous publication, we provided an overview of the current situation of patient access to orphan drugs in the European Union (EU), of the evolving rare disease policy landscape and recommendations for...
Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis [0.03%]
帕金森病冻结步态结局测量指标的心理测量属性：系统评价和荟萃分析
Prisca Proietti,Ilaria Ruotolo,Alessandra Carlizza et al.
Prisca Proietti et al.
Introduction: This systematic review and meta-analysis aimed to evaluate validated tools for assessing FOG in individuals with PD, focusing on their psychometric properties, linguistic adaptations, and methodological qual...
Ana Bobinac,Luka Vončina,Ismar Velić et al.
Ana Bobinac et al.
Background: Rising pharmaceutical expenditure worldwide, including in Croatia, is putting considerable pressure on healthcare budgets. Oncology drugs, often used in several indications with varying efficacy, contribute to...